morphine sulfate; naltrexone hydrochloride
EMBEDA (morphine sulfate; naltrexone hydrochloride) is ] . Approved for moderate to severe pain, around-the-clock opioid analgesic is needed for an extended period of time. First approved in 2009.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
EMBEDA is an extended-release oral capsule combining morphine sulfate (a mu-opioid agonist) with naltrexone hydrochloride (a mu-opioid antagonist) for moderate to severe pain requiring around-the-clock opioid therapy. The naltrexone component is designed to reduce opioid-induced gastrointestinal side effects, particularly constipation, by antagonizing mu-opioid receptors in the gut while maintaining systemic analgesia. This dual-mechanism approach addresses a major tolerability barrier in chronic opioid therapy.
Product is in peak commercial maturity with 15 years post-launch history; competitive pressure score of 8/10 indicates mature market environment requiring defensive positioning and efficiency.
] . Effects on the Gastrointestinal Tract and Other Smooth Muscle Gastric, biliary, and pancreatic secretions are decreased by morphine. Morphine causes a reduction in motility associated with an increase in tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is…
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain
Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
Conversion to Embeda With Rescue Trial
Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~4 years — strategic planning for patent cliff underway
Working on EMBEDA offers limited career advancement given mature peak lifecycle and imminent LOE (3.6 years); roles focus on defensive market share retention, managed decline, and transition planning rather than growth. Most suitable for experienced professionals seeking stability in a declining franchise or early-career professionals willing to manage a sunset product for process and stakeholder management experience.